What is DnaNudge?
Founded in 2015 and headquartered in the United Kingdom, DnaNudge specializes in leveraging DNA testing to advance research in critical health areas including hypertension, cholesterol management, and type two diabetes. The company's innovative approach aims to provide personalized insights, contributing to a more proactive healthcare paradigm. As a key player in the health-tech industry, DnaNudge is focused on translating genetic data into actionable health information for both research institutions and potentially consumers.
How much funding has DnaNudge raised?
DnaNudge has raised a total of $60M across 1 funding round:
Series A
$60M
Series A (2021): $60M with participation from Bank Julius Baer and Ventura Capital
Key Investors in DnaNudge
Bank Julius Baer
Bank Julius Baer is a prominent private banking group, likely providing strategic financial backing and advisory services to companies within its investment portfolio.
Ventura Capital
Ventura Capital is an investment firm that typically focuses on providing capital for growth-stage companies, potentially specializing in the health or technology sectors.
What's next for DnaNudge?
The recent major strategic investment signifies a pivotal moment for DnaNudge, likely enabling the company to accelerate its product development, scale its operations, and potentially expand its research into new therapeutic areas. This infusion of capital, part of its $60M in total financing, suggests strong investor confidence in DnaNudge's technology and its potential to disrupt the diagnostics market. Future endeavors may include broader clinical validation, strategic partnerships, and the commercialization of its testing platforms.
See full DnaNudge company page
